Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
eNq1mF1v2jAUhu/5FVHuSZpSaDsFqo21G1KrMVq0aTfIJIdiFuz02Oajv34OoRtMjtoafBnbec+Jz+vHR4mvVvPMWwAKylnbj4IT3wOW8JSyx7Y/fLipX/hXnVo8Iwuys+w8OAmiU99LMiJE2y9mgzEQJoKfd7efQb8P6HdqXszHM0jk3jolaRZ8JWJ6R/JijRcvOE29OcgpT9t+ruRm1IuFRJ1FZ8nxt8hJAnG4HdmdnY3OdsfjsBB7g6oSgLeEPRpFgVlpJgoRmOwSCY8c1xX5Nqy0qRiA4AoT6BM57SNf0BRSY4gJyQRYBZks03vARQayCGIUD2fJXFiJkxlZDeCpZ076o57typWsn9Sj82ar1Wo0LqLG2alVKNzZKnMV9EeEyShqNC/Pz5ohsHC+5s/rOVjWps9RksxRVajo7hvLURyEp1ern1KRZ2QdzERuu1UEiZ4G1Mff3YcUX/CAGkiZ3rP/9JnKsvCdWQ+3uHCUcUGjLldMVlDjZmC7EV3OJKyqK2oHOrnaepGCOJ7sM2dmyPfVOKOJLdI0dBQIORz0qol2TBh8IgKG6I4GPyhL+VIcnzK7VXWUfb4BpVE0xzQanV5etKJm0/oQ/dIWqrhhrhXyHELNHyoOwUqPTfihQNGuNEu9ePJodtz0OTwhGVR0OnVLtmgfvjRmzpzu7hSVE0bRL9cPtvb4rgDX95tHozRN238LawdeFzTXZqxM/P3WLk+4kx5YoZkcUylz8SEMp0TUBdE7FEzw6FTfuUjddd9ObuuyeynJ6Cj1cXnlvb06tifstbv80P50+/62DzbGkKjggDqUMHaGzN718Sn8rzl1lnZ/jxruwmwaSSIpZ64aHDU2Kh7GfV1XdoMaDt8mE1rxJ6TSl3FY/oXp1OKw+APTqf0Bya/iWw==
GSGMm0NzqJ00Ths9
Listen
